| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 121 | 2025 | 874 | 24.620 |
Why?
|
| Autoantibodies | 46 | 2025 | 466 | 7.620 |
Why?
|
| Diabetes Mellitus, Type 2 | 29 | 2025 | 1419 | 6.540 |
Why?
|
| C-Peptide | 28 | 2025 | 116 | 4.940 |
Why?
|
| Islets of Langerhans | 19 | 2024 | 178 | 4.540 |
Why?
|
| Insulin Resistance | 10 | 2025 | 700 | 3.130 |
Why?
|
| Insulin | 29 | 2025 | 1260 | 2.860 |
Why?
|
| Diabetic Ketoacidosis | 12 | 2024 | 169 | 2.330 |
Why?
|
| Blood Glucose | 23 | 2025 | 1195 | 2.320 |
Why?
|
| Adolescent | 78 | 2025 | 20646 | 2.000 |
Why?
|
| Autoimmunity | 13 | 2020 | 182 | 1.940 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2025 | 2949 | 1.890 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 6 | 2022 | 25 | 1.820 |
Why?
|
| Child | 81 | 2025 | 25917 | 1.750 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2025 | 3509 | 1.730 |
Why?
|
| Hypoglycemic Agents | 12 | 2024 | 491 | 1.720 |
Why?
|
| HLA-DQ Antigens | 7 | 2024 | 22 | 1.700 |
Why?
|
| Glucose Tolerance Test | 13 | 2025 | 227 | 1.520 |
Why?
|
| Insulin-Secreting Cells | 7 | 2024 | 150 | 1.490 |
Why?
|
| Humans | 149 | 2025 | 134196 | 1.390 |
Why?
|
| Diabetes Complications | 2 | 2023 | 206 | 1.280 |
Why?
|
| Child, Preschool | 45 | 2025 | 14897 | 1.230 |
Why?
|
| Disease Progression | 22 | 2025 | 2265 | 1.130 |
Why?
|
| Male | 86 | 2025 | 66197 | 1.110 |
Why?
|
| Glutamate Decarboxylase | 6 | 2017 | 42 | 1.100 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 143 | 1.090 |
Why?
|
| Female | 87 | 2025 | 72037 | 1.080 |
Why?
|
| Young Adult | 30 | 2025 | 9961 | 1.020 |
Why?
|
| HLA-DR3 Antigen | 1 | 2024 | 1 | 0.930 |
Why?
|
| HLA-DR4 Antigen | 1 | 2024 | 6 | 0.930 |
Why?
|
| Hypoglycemia | 6 | 2018 | 193 | 0.890 |
Why?
|
| Adult | 46 | 2025 | 31948 | 0.880 |
Why?
|
| Body Mass Index | 10 | 2023 | 1722 | 0.870 |
Why?
|
| Risk Factors | 27 | 2025 | 11189 | 0.850 |
Why?
|
| Immunoglobulin A | 2 | 2024 | 217 | 0.830 |
Why?
|
| Leptin | 2 | 2023 | 224 | 0.800 |
Why?
|
| Puberty | 2 | 2021 | 104 | 0.790 |
Why?
|
| Minority Groups | 3 | 2020 | 255 | 0.760 |
Why?
|
| Obesity | 10 | 2022 | 2448 | 0.720 |
Why?
|
| Biomarkers | 9 | 2024 | 3433 | 0.720 |
Why?
|
| Infant | 24 | 2024 | 13262 | 0.720 |
Why?
|
| Metformin | 1 | 2023 | 165 | 0.720 |
Why?
|
| Pediatric Obesity | 5 | 2021 | 413 | 0.720 |
Why?
|
| Genetic Linkage | 2 | 2021 | 482 | 0.700 |
Why?
|
| Hyperglycemia | 4 | 2020 | 242 | 0.690 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 115 | 0.670 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 320 | 0.650 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 349 | 0.650 |
Why?
|
| Cohort Studies | 18 | 2025 | 5219 | 0.620 |
Why?
|
| Overweight | 7 | 2020 | 387 | 0.580 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3760 | 0.570 |
Why?
|
| Flatfishes | 3 | 2006 | 3 | 0.570 |
Why?
|
| Fish Diseases | 3 | 2006 | 11 | 0.570 |
Why?
|
| Age of Onset | 6 | 2020 | 638 | 0.560 |
Why?
|
| Prospective Studies | 16 | 2024 | 6612 | 0.560 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 319 | 0.550 |
Why?
|
| Adiposity | 2 | 2020 | 207 | 0.550 |
Why?
|
| Phenotype | 9 | 2024 | 4610 | 0.550 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 937 | 0.540 |
Why?
|
| Age Factors | 12 | 2024 | 2997 | 0.540 |
Why?
|
| Precision Medicine | 4 | 2024 | 361 | 0.530 |
Why?
|
| Osteocalcin | 1 | 2017 | 50 | 0.520 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2025 | 11 | 0.520 |
Why?
|
| Protozoan Infections, Animal | 2 | 2006 | 4 | 0.510 |
Why?
|
| Prediabetic State | 3 | 2015 | 63 | 0.500 |
Why?
|
| Prognosis | 8 | 2024 | 5084 | 0.500 |
Why?
|
| Twins, Monozygotic | 3 | 2008 | 129 | 0.490 |
Why?
|
| Hospitalization | 1 | 2024 | 1913 | 0.480 |
Why?
|
| Diseases in Twins | 2 | 2008 | 99 | 0.460 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 66 | 0.430 |
Why?
|
| Thinness | 1 | 2014 | 77 | 0.430 |
Why?
|
| Middle Aged | 24 | 2025 | 29414 | 0.420 |
Why?
|
| Glucose | 5 | 2023 | 926 | 0.400 |
Why?
|
| Haplotypes | 7 | 2024 | 559 | 0.380 |
Why?
|
| Health Personnel | 1 | 2017 | 542 | 0.380 |
Why?
|
| Retrospective Studies | 11 | 2025 | 17579 | 0.370 |
Why?
|
| Family | 4 | 2025 | 597 | 0.370 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 920 | 0.360 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 124 | 0.360 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 722 | 0.360 |
Why?
|
| Sex Factors | 6 | 2024 | 1388 | 0.350 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5465 | 0.330 |
Why?
|
| Patient Preference | 1 | 2011 | 136 | 0.330 |
Why?
|
| Eukaryota | 2 | 2006 | 25 | 0.310 |
Why?
|
| Antibody Specificity | 3 | 2018 | 203 | 0.300 |
Why?
|
| Prevalence | 6 | 2024 | 2684 | 0.300 |
Why?
|
| Mass Screening | 3 | 2025 | 843 | 0.300 |
Why?
|
| Social Class | 3 | 2020 | 210 | 0.290 |
Why?
|
| Zinc Transporter 8 | 3 | 2017 | 6 | 0.290 |
Why?
|
| HLA Antigens | 3 | 2025 | 221 | 0.280 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 658 | 0.270 |
Why?
|
| Twins, Dizygotic | 2 | 2004 | 48 | 0.270 |
Why?
|
| Genetic Testing | 3 | 2024 | 1105 | 0.260 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2006 | 39 | 0.250 |
Why?
|
| Abatacept | 1 | 2025 | 27 | 0.240 |
Why?
|
| Major Histocompatibility Complex | 4 | 2017 | 53 | 0.240 |
Why?
|
| Dyslipidemias | 2 | 2021 | 246 | 0.240 |
Why?
|
| Cluster Analysis | 2 | 2024 | 440 | 0.240 |
Why?
|
| Health Status Disparities | 2 | 2020 | 252 | 0.240 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2091 | 0.240 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2024 | 18 | 0.220 |
Why?
|
| Social Determinants of Health | 2 | 2023 | 158 | 0.220 |
Why?
|
| Weight Gain | 3 | 2017 | 414 | 0.210 |
Why?
|
| Alleles | 5 | 2017 | 1724 | 0.210 |
Why?
|
| Cytokines | 3 | 2024 | 1397 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2024 | 750 | 0.210 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 75 | 0.210 |
Why?
|
| Siblings | 1 | 2004 | 202 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 556 | 0.200 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 45 | 0.200 |
Why?
|
| Genetic Vectors | 2 | 2017 | 967 | 0.200 |
Why?
|
| Immunity, Innate | 1 | 2006 | 415 | 0.200 |
Why?
|
| Fabaceae | 1 | 2023 | 27 | 0.200 |
Why?
|
| United States | 10 | 2025 | 11798 | 0.200 |
Why?
|
| Area Under Curve | 4 | 2025 | 333 | 0.190 |
Why?
|
| Immune System | 2 | 2020 | 98 | 0.190 |
Why?
|
| Acanthosis Nigricans | 1 | 2022 | 11 | 0.190 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 71 | 0.190 |
Why?
|
| Self-Management | 2 | 2020 | 104 | 0.190 |
Why?
|
| Genotype | 5 | 2018 | 2822 | 0.180 |
Why?
|
| Celiac Disease | 2 | 2017 | 73 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2020 | 337 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 869 | 0.180 |
Why?
|
| Longitudinal Studies | 5 | 2025 | 1512 | 0.170 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.170 |
Why?
|
| Interleukin-4 | 2 | 2005 | 148 | 0.170 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 41 | 0.170 |
Why?
|
| Early Diagnosis | 1 | 2021 | 201 | 0.160 |
Why?
|
| HLA-DR2 Antigen | 1 | 1999 | 6 | 0.160 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 10 | 0.160 |
Why?
|
| HLA-DQ alpha-Chains | 4 | 2017 | 18 | 0.160 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 33 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 27 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2024 | 1630 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 483 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 133 | 0.160 |
Why?
|
| Spain | 5 | 2007 | 65 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 278 | 0.160 |
Why?
|
| Models, Immunological | 2 | 2015 | 38 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 1125 | 0.150 |
Why?
|
| Global Health | 1 | 2024 | 623 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 59 | 0.150 |
Why?
|
| Cation Transport Proteins | 2 | 2017 | 101 | 0.150 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 182 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 81 | 0.140 |
Why?
|
| Registries | 4 | 2022 | 1588 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 800 | 0.140 |
Why?
|
| Seasons | 3 | 2006 | 334 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 320 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2318 | 0.130 |
Why?
|
| Leg | 1 | 1997 | 142 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 288 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 780 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 60 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1193 | 0.130 |
Why?
|
| Communication | 2 | 2019 | 542 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 271 | 0.130 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 43 | 0.130 |
Why?
|
| Retroviridae | 1 | 2016 | 198 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2001 | 112 | 0.120 |
Why?
|
| Glucagon | 1 | 2016 | 184 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 69 | 0.120 |
Why?
|
| Exercise | 1 | 2022 | 872 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 237 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 67 | 0.120 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 76 | 0.120 |
Why?
|
| Roma | 1 | 1995 | 4 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 1995 | 5 | 0.120 |
Why?
|
| Time Factors | 5 | 2016 | 6595 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 79 | 0.120 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 912 | 0.120 |
Why?
|
| Child Development | 1 | 2017 | 286 | 0.120 |
Why?
|
| Diabetic Foot | 1 | 1997 | 167 | 0.120 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 362 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 252 | 0.110 |
Why?
|
| Language | 1 | 2016 | 222 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 444 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 154 | 0.110 |
Why?
|
| Adipokines | 1 | 2014 | 73 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 503 | 0.110 |
Why?
|
| Nuclear Family | 1 | 2013 | 51 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2017 | 648 | 0.100 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 897 | 0.100 |
Why?
|
| Lignans | 1 | 2012 | 7 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2020 | 8639 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 438 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1595 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 54 | 0.100 |
Why?
|
| Insulin Antibodies | 3 | 2017 | 7 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 652 | 0.090 |
Why?
|
| Pancreas, Artificial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Flavonoids | 1 | 2012 | 87 | 0.090 |
Why?
|
| Self Administration | 1 | 2011 | 45 | 0.090 |
Why?
|
| Twin Studies as Topic | 2 | 2001 | 15 | 0.090 |
Why?
|
| Stem Cells | 1 | 2016 | 754 | 0.090 |
Why?
|
| Random Allocation | 2 | 2016 | 446 | 0.090 |
Why?
|
| Oxazolidinones | 2 | 2001 | 34 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 387 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2025 | 13103 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2163 | 0.090 |
Why?
|
| Pedigree | 3 | 2021 | 1732 | 0.080 |
Why?
|
| Comorbidity | 3 | 2022 | 1627 | 0.080 |
Why?
|
| Diet | 2 | 2012 | 1194 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 1308 | 0.080 |
Why?
|
| Aquaculture | 2 | 2006 | 9 | 0.080 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 19 | 0.080 |
Why?
|
| Pregnancy | 1 | 2022 | 7600 | 0.080 |
Why?
|
| Risk | 3 | 2017 | 833 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3753 | 0.080 |
Why?
|
| Animals | 10 | 2017 | 36521 | 0.080 |
Why?
|
| Autoantigens | 2 | 2001 | 118 | 0.080 |
Why?
|
| Incidence | 4 | 2013 | 3424 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2016 | 890 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1486 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 133 | 0.070 |
Why?
|
| Aged | 8 | 2019 | 21805 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1772 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 1041 | 0.070 |
Why?
|
| Spleen | 2 | 2006 | 289 | 0.070 |
Why?
|
| Calpain | 1 | 2007 | 43 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 1493 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1492 | 0.060 |
Why?
|
| Depression | 1 | 2015 | 1365 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 567 | 0.060 |
Why?
|
| Immunity, Active | 1 | 2006 | 6 | 0.060 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 6 | 0.060 |
Why?
|
| Hypertension | 1 | 2015 | 1407 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 28 | 0.060 |
Why?
|
| Complement Pathway, Alternative | 1 | 2006 | 14 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 103 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 55 | 0.060 |
Why?
|
| Muramidase | 1 | 2006 | 99 | 0.060 |
Why?
|
| Granulocytes | 1 | 2006 | 71 | 0.060 |
Why?
|
| Pediatrics | 1 | 2015 | 1221 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 100 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 145 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1070 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2004 | 34 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3678 | 0.060 |
Why?
|
| Probability | 1 | 2025 | 334 | 0.060 |
Why?
|
| Acetamides | 2 | 2001 | 51 | 0.060 |
Why?
|
| Family Health | 2 | 2005 | 268 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2016 | 185 | 0.050 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 318 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 105 | 0.050 |
Why?
|
| Neoplasms | 2 | 2013 | 3035 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 15 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 68 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 725 | 0.050 |
Why?
|
| Europe | 2 | 2013 | 382 | 0.050 |
Why?
|
| Teicoplanin | 1 | 2001 | 5 | 0.050 |
Why?
|
| Coagulase | 1 | 2001 | 23 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2006 | 1595 | 0.050 |
Why?
|
| Citrulline | 1 | 2023 | 114 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 222 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 79 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 452 | 0.050 |
Why?
|
| Mesonephroma | 1 | 2001 | 1 | 0.050 |
Why?
|
| Papilloma | 1 | 2001 | 22 | 0.050 |
Why?
|
| Methicillin Resistance | 1 | 2001 | 118 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 19 | 0.040 |
Why?
|
| Self Tolerance | 1 | 2001 | 6 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 106 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 351 | 0.040 |
Why?
|
| Aza Compounds | 1 | 2000 | 15 | 0.040 |
Why?
|
| United Kingdom | 1 | 2001 | 242 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 201 | 0.040 |
Why?
|
| Streptococcus | 1 | 2000 | 63 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 241 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 564 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 727 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2000 | 97 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 682 | 0.040 |
Why?
|
| Quinolines | 1 | 2000 | 114 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1221 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2001 | 2588 | 0.040 |
Why?
|
| Colectomy | 1 | 2019 | 84 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1404 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 972 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1183 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 111 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 401 | 0.040 |
Why?
|
| Artificial Limbs | 1 | 1997 | 7 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 611 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 480 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1997 | 22 | 0.040 |
Why?
|
| Pinealoma | 1 | 1997 | 23 | 0.040 |
Why?
|
| Germinoma | 1 | 1997 | 32 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2001 | 790 | 0.030 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 78 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 205 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2020 | 333 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 72 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 7239 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 165 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 480 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 406 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 194 | 0.030 |
Why?
|
| Learning | 1 | 2020 | 375 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 85 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 199 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 33 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 948 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 810 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 132 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 233 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1982 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 242 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 296 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1391 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 2863 | 0.030 |
Why?
|
| Rural Health | 1 | 1995 | 52 | 0.030 |
Why?
|
| Urban Health | 1 | 1995 | 79 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 851 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 768 | 0.030 |
Why?
|
| Mice | 4 | 2017 | 19045 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 333 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1685 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4008 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 232 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 596 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 1098 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 248 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 2213 | 0.030 |
Why?
|
| Palliative Care | 1 | 2018 | 464 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 168 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2001 | 1621 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 825 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2170 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1332 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 42 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 628 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 838 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2013 | 76 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 1995 | 145 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 874 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 508 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1344 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1735 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1393 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1100 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 638 | 0.020 |
Why?
|
| Linezolid | 2 | 2001 | 27 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 506 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 1357 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2538 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1739 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1144 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2001 | 8 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 506 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 463 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 2178 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3119 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 1406 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 2735 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 11 | 0.020 |
Why?
|
| Israel | 1 | 2005 | 48 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 69 | 0.010 |
Why?
|
| Arabs | 1 | 2005 | 30 | 0.010 |
Why?
|
| Jews | 1 | 2005 | 35 | 0.010 |
Why?
|
| Atlantic Ocean | 1 | 2004 | 2 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2005 | 100 | 0.010 |
Why?
|
| Oocysts | 1 | 2004 | 4 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2004 | 22 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 137 | 0.010 |
Why?
|
| Glutens | 1 | 2004 | 10 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2004 | 27 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 570 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 448 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1044 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 291 | 0.010 |
Why?
|
| Denmark | 1 | 2001 | 29 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 3 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 13 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 258 | 0.010 |
Why?
|
| Virginiamycin | 1 | 2000 | 3 | 0.010 |
Why?
|
| Naphthyridines | 1 | 2000 | 10 | 0.010 |
Why?
|
| Erythromycin | 1 | 2000 | 21 | 0.010 |
Why?
|
| Oxazoles | 1 | 2000 | 23 | 0.010 |
Why?
|
| Epithelium | 1 | 2001 | 365 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 199 | 0.010 |
Why?
|
| Vagina | 1 | 2001 | 205 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 816 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 433 | 0.010 |
Why?
|
| Environment | 1 | 2000 | 156 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 397 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 835 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1622 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 617 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1945 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1721 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 3868 | 0.000 |
Why?
|